

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Lee D. Jennings

Confirmation No.: 5557

Application No.: 10/731,723

Group Art Unit: 1626

Filing Date: December 9, 2003

Examiner: Golam M. Shameem

For: Substituted 3-Carbonyl-1h-Indol-1yl Acetic Acid Derivatives As Inhibitors Of Plasminogen Activator Inhibitor-1 (Pai-1)

EXPRESS MAIL LABEL NO: EV 614726103 US
DATE OF DEPOSIT: October 11, 2005PLACE EXPRESS MAIL LABEL
PEEL OFF STICKER HERE

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

Certification in Accordance with § 1.97(e) is attached; or

The fee of \$180.00 as set forth in § 1.17(p) is attached.

In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

Copies of reference numbers 48-58 listed on the attached Form PTO-1449 are enclosed herewith.

Copies of reference numbers 41-47 listed on the attached Form PTO 1449 are not required to be submitted pursuant to the waiver of 37 CFR § 1.98(a)(2)(i).

Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

The relevance of those listed references which are not in the English language is as follows:


DOCKET NO.: AM100635/WYNC-0995-3 -

PATENT

English language abstracts have been provided for those listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: October 11, 2005



Leslie E. Aberman
Registration No. 54,836

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



Form PTO-1449 Modified

**List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)**

U.S. Department of Commerce
Patent and Trademark Office

Docket No. AM100635/WYNC-0995	Application No. 10/731,723
Applicant Lee D. Jennings	
Filing Date December 9, 2003	Group 1626
Confirmation No. 5557	

U. S. PATENT DOCUMENTS

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. AM100635/ WYNC-0995	Application No. 10/731,723
		Applicant Lee D. Jennings	
		Filing Date December 9, 2003	Group 1626
		Confirmation No. 5557	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	58	Charlton, Peter, "The status of plasminogen activator inhibitor-1 as a therapeutic target," <i>Expert Opinion On Investigational Drugs</i> , (May 1997), vol. 6, no. 5, pages 539-554	
EXAMINER		DATE CONSIDERED	